Evidence map›Paper›PMID 41141501›Full record

ArticleKidney international reports2025

Sex Differences Across Corticosteroid Response and Outcomes in IgA Nephropathy.

Dana Kim, Mark Woodward, Jicheng Lv, Michelle A Hladunewich, Vivekanand Jha, Lai Seong Hooi, Helen Monaghan, Vlado Perkovic, Hong Zhang, Muh Geot Wong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dana KimThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Mark WoodwardThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Jicheng LvRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Michelle A HladunewichDivision of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine University of Toronto, Toronto, Ontario, Canada.
Vivekanand JhaSchool of Public Heath, The George Institute for Global Health, Imperial College London, London, UK.
Lai Seong HooiDepartment of Medicine and Haemodialysis Unit, Sultanah Aminah Hospital, Johor Bahru, Malaysia.
Helen MonaghanThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Vlado PerkovicThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Hong ZhangRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Muh Geot WongThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
TESTING Trial Steering Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The impact of sex on treatment response and outcomes in IgA nephropathy (IgAN) remains uncertain. This analysis of the Therapeutic Effects of Steroids in IgAN Global (TESTING) trial aimed to evaluate the following: (i) the effect of sex on corticosteroid response and (ii) the association between sex and kidney outcomes in IgAN. Methods: Participants with IgAN were randomized to 6 to 9 months of oral methylprednisolone or placebo. The primary outcome was a composite of 40% decline in estimated glomerular filtration rate (eGFR), kidney failure, or death because of kidney disease. The interaction between sex and treatment on the risk of the primary outcome, relative change in proteinuria, and total eGFR slope was tested. Cox models were used to estimate the risk of the primary outcome in males versus females. Sex differences in total eGFR slope were also estimated. Results: Overall, there were 305 males (61%) and 198 females (39%). The mean follow-up period was 4.2 years. Compared with placebo, methylprednisolone lowered the risk of the primary outcome in both males (hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.35-0.74) and females (HR: 0.64, 95% CI: 0.38-1.09) ( Conclusion: Methylprednisolone improves kidney outcomes in IgAN, regardless of sex; however, males experience poorer kidney outcomes than females.

Indexed as

clinical trialscorticosteroidsIgA nephropathysex

Identifiers

PMID41141501
PMCPMC12545885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.